Skip to main content
. 2019 Sep 10;8(15):6549–6558. doi: 10.1002/cam4.2539

Table 1.

Characteristics of patients with AIHA

No Gender Age Diagnosis Donor type Type of AIHA Time to AIHA cGVHD Immunosuppressive therapies at the onset of AIHA Initial treatment AIHA relapse Underlying disease relapse
1 Male 46 AML HRD Evans 245 Yes MMF(0.25 g2/d) + tacrolimus (0.5 mg 2/d) GC + CsA No No
2 Male 21 MDS HRD Evans 203 Yes MMF(0.25 g 2/d) + CsA (150 mg 1/d) + methylprednisolone (32 mg 1/d) GC + CsA No No
3 Male 18 T‐LBL MUD AIHA 312 No CsA (50 mg 2/d) + methylprednisolone (32 mg 1/d) GC + CsA No No
4 Male 25 AML HRD Evans 133 Yes CsA (50 mg 2/d) + methylprednisolone (20 mg 1/d) GC + CsA No No
5 Male 37 ALL HRD AIHA 189 No Methylprednisolone (60 mg 1/d) —a —a No
6 Male 38 AUL MSD AIHA 375 Yes Methylprednisolone (40 mg 1/d) + prograf (1.5 mg 2/d) GC + CsA —b No
7 Female 29 ALL MSD AIHA 756 No methylprednisolone(32 mg 1/d) GC + CsA No No
8 Female 46 MDS HRD Evans 60 No MMF (0.5 g 2/d) + CsA (50 mg 2/d) + methylprednisolone (40 mg 3/d) GC + CsA No No
9 Female 20 ALL HRD AIHA 140 No MMF (0.25 g 1/d) + CsA (50 mg 2/d) + methylprednisolone (40 mg 1/d) GC + CsA —b No
10 Male 18 ALL HRD Evans 104 No MMF (0.2 g 2/d) + tacrolimus (0.5 mg 2/d) + methylprednisolone (40 mg 1/d) GC + CsA —b No
11 Male 16 ALL MUD AIHA 154 Yes CsA (50 mg 2/d) + methylprednisolone (32 mg 1/d) GC + CsA No No
12 Male 19 ALL HRD Evans 203 No MMF(0.5 g 2/d) + CsA (50 mg 2/d) + methylprednisolone (40 mg 3/d) GC + CsA No No
13 Male 22 ALL MUD AIHA 252 Yes — GC + CsA No No
14 Male 22 AML HRD AIHA 215 Yes — GC No No
15 Male 44 AML MUD Evans 111 Yes CsA (25 mg 2/d) GC Yes No
16 Male 44 ALL MSD AIHA 258 Yes — GC —b No
17 Female 15 ALL HRD AIHA 34 No MMF (0.25 g 2/d) + tacrolimus (0.5 mg 2/d) GC + CsA No No
18 Female 36 AML HRD AIHA 134 Yes MMF (0.25 g 2/d) + CsA (150 mg 1/d) + methylprednisolone (32 mg 1/d) GC Yes No
19 Female 31 ALL HRD AIHA 139 Yes CsA (50 mg 2/d) + methylprednisolone (32 mg 1/d) GC —b No
20 Male 20 ALL MSD AIHA 254 Yes — GC Yes No
21 Female 27 ALL HRD AIHA 349 Yes — GC Yes No
22 Female 26 ALL HRD AIHA 263 Yes — GC —c No
23 Male 18 AML HRD AIHA 250 Yes — GC No No
24 Female 22 AML MUD AIHA 220 Yes MMF (0.5 g 2/d) + CsA (50 mg 2/d) + methylprednisolone (40 mg 3/d) GC + CsA No No
25 Female 34 AML MSD AIHA 197 No — GC + CsA No No
26 Female 21 AML MUD AIHA 228 Yes — GC No Yes

Abbreviations: AIHA, autoimmune hematological diseases; ALL, acute lymphocytic leukemia; AML, acute myeloid leukemia; AUL, acute undifferentiated leukemia; CsA, cyclosporine A; GC, glucocorticoid; HRD, haploidentical‐related donor; MDS, myelodysplastic syndrome; MMF, mycophenolate mofetil; MSD, matched sibling donor; MUD, matched unrelated donor; T‐LBL, T‐lymphoblastic lymphoma.

a

This patient died of infectious shock 2 days after the diagnosis of AIHA and was excluded from AIHA treatment and relapse analyses.

b

These patients received corticosteroids combined CsA treatment who obtained no response after the 4 weeks' initial treatment changed their regimen by adding second‐line treatments so that was excluded from AIHA relapse analyses.

c

This patient received corticosteroids monotherapy who did not response to the 2 weeks' initial treatment changed their regimen by adding CsA so that was excluded from AIHA relapse analyses.